New Jersey Aims to Ensure That All Children Have Health Insurance

John Klein has led Teaneck, New Jersey-based Cambridge Therapeutics since founding the pharmaceutical products manufacturer nearly a decade ago. He and his company provide a range of customer-friendly medical packaging options designed to increase patient adherence to prescription regimens. In addition to his role with Cambridge Therapeutics, John Klein is a board member with Hackensack Meridian Health Hospitals and regularly studies emerging information in the healthcare field in his state.

In order to care for the most vulnerable of its citizens, the state of New Jersey oversees NJFamilyCare, a publicly funded insurance program that offers free or affordable health insurance for individuals of all ages. The program entitles policy holders to obtain visits to physicians, dentists, mental health professionals, and vision care specialists, as well as hospital services.

However, the research group New Jersey Policy Perspective noted that the number of children enrolled in NJFamilyCare has decreased over the past year. And a new study shows that there remain significant gaps in levels of health insurance coverage stemming from ethnic, geographic, and socioeconomic differences. Simply put, there are a large number of children in New Jersey - estimates put the number at close to 80,000 - who need subsidized health insurance, but whose families have not yet taken advantage of it.

New Jersey lawmakers have stated their goal of expanding this coverage. They plan to direct specialized outreach efforts to communities of color and to work to eliminate barriers to enrollment that may exist for immigrant families and other particularly vulnerable groups.

Comments

Bilogix Implements Enterprise Performance Management Solutions

The chairman of Alpine, New Jersey-based Cambridge Therapeutics, John Klein offers next-generation solutions in areas ranging from combination therapies to drug delivery. Building on his experience with Cambridge Therapeutics, John Klein recently launched Bilogix in Alpine, NJ, a provider of enterprise performance management (EPM) consulting services. Encompassing processes and applications, the EPM approach is one that transforms key performance indicator (KPI) data into highly accurate ways of analyzing, monitoring, measuring, and forecasting organizational results. It adds value through bringing focus on the details of how strategic plans are envisioned and implemented, as well as how challenges and inconsistencies are addressed when they occur. This ensures that resources are utilized more efficiently toward defined goals, at both the operational and tactical levels. At the same time, the effects of business intelligence investments can be tracked via a dashboard and r

Enterprise Performance Management Enables Strategic Realignment

Longtime Alpine, NJ entrepreneur John Klein serves as the CEO of Cambridge Therapeutics, where he guides innovation-focused pharmaceutical development. Using his experience at Cambridge Therapeutics in New Jersey, John Klein founded Bilogix, a consulting company that provides client-specific enterprise performance management (EPM) solutions. By monitoring and quantifying key performance indicators, EPM analyzes and measures business applications and processes. Ideal for companies with many moving parts, EPM takes complex data and delivers predictive solutions that follow the Six Sigma mandate of eliminating waste. Six Sigma is a logically structured set of processes designed to identify and eliminate issues impacting efficiency within an operation. Processes can be aligned with specific workforce requirements and resources directed in ways that maximize output, both in terms of employee allocation and bottom-line revenue. The EPM approach relies on a business intelligence (BI

NJ Attorney General Reveals Measures to Combat Opioid Epidemic

The chairman of Cambridge Therapeutics in Teaneck, New Jersey, John Klein has obtained FDA approval for more than 300 generic drugs in the course of his 30-year career. His work at Cambridge Therapeutics has resulted in honors including high ranking on Forbes’ list of the Top 100 CEOs. Complementing that work, John Klein closely follows health and related developments in New Jersey. The state’s attorney general, Gurbir Grewal, recently announced new efforts aimed at battling the state’s opioid epidemic. Grewal has proposed a rule change to make medication-assisted treatment, long recognized as the most effective way to treat opioid addiction, more widely available to the state’s residents through use of telemedicine technology. Allowing physicians to assess and prescribe treatments to patients through two-way, real-time video communication will ensure more people can access medication-assisted treatment and improve their odds of surviving their opioid addiction. In addition, Grewa

John Klein - Guiding Cambridge Therapeutics in New Jersey

Search This Blog